Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, October 21, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Plate Reader versus High Content RNAi Screens. Who's Right?
  Videos

Return

Plate Reader versus High Content RNAi Screens. Who's Right?
Sheffield University

There are few research areas that have expanded as quickly and spectacularly as the field of RNA interference (RNAi). RNAi based research is now maturing into a multi-billion pound industry. The notion that we can systematically switch off every gene in the genome and screen for important biological processes has become both practical and routine. Marrying this technology with High Content Microscopy we are capable of asking important phenotypic questions in a systematic way. The Sheffield RNAi Screening Facility was born from the fundamentals of the initially highly successful Drosophila melanogaster screening platform and now we operate both the Fruit Fly and Human systems. Due to the ability to compare two screens from different organisms for the first time, results will be presented from a high content siRNA screen in a Human cell line, comparing results to previously intensive screens from 3 genome-wide Drosophila screens completed using a plate reader platform. We will present the benefits and difficulties of both cellular platforms. While presenting the results, we will discuss issues such as the complexities of the type of screening approach adopted.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
New Test can Help Doctors Choose Best Treatment for Ovarian Cancer
ADNEX discriminate between benign and malignant tumours with a high level of accuracy.
All the Cell’s a Stage
Brian Strahl, PhD, and his band of biochemists unravel the complicated mysteries of the epigenetic code to find a culprit in cancer development.
New Cancer Drug To Begin Trials In Multiple Myeloma Patients
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.
ISB Gets $6.5 Million from NCI
Company has received two-year contract to create ‘Cancer Genomics Cloud’ with partners Google and SRA International.
Precise Control Over Genes Results from Game-Changing Research
UCSF invention greatly amplifies power of CRISPR technology.
Unusual Skin Cancer Linked To Chronic Allergy
Scientists have learned that inflammation at the site of an allergic skin rash can promote skin tumor formation if it persists.
New Clues For Early Colorectal Cancer Detection
Study identifies new biomarkers which could help detect colorectal cancer.
New 'Lab-on-a-Chip' Could Revolutionize Early Diagnosis of Cancer
Faster result times, reduced costs, minimal sample demands and better sensitivity of analysis.
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Personalized Ovarian Cancer Vaccines
UConn Researchers have found a new way to identify protein mutations in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv